Business Wire

NY-SECURITYSCORECARD

Share
SecurityScorecard Enables Organizations to View Risks and Measure the ROI of Security Investments in the Midst of Turbulent Economic Times

SecurityScorecard, the global leader in cybersecurity ratings, today announced it has launched a series of resources designed to help organizations navigate increased scrutiny of budgets and ensure that security efforts get the funding needed to support the business.

The content and tools will make it easier for organizations to realize and demonstrate the return on their security program.

Economic uncertainty is affecting organizations across industries. While expenditures are being scrutinized, cybersecurity budgets are no exception, and bad actors often take advantage of these turbulent times. Therefore It's more important than ever for security leaders to articulate the value of their security and vendor risk management programs and effectively communicate clear ROI for technology investments.

The resources include the ebook 5 Ways to Secure Your Organization In Turbulent Times, and SecurityScorecard's Return on Investment (ROI) Calculator, a free high-level estimate of the Total Economic Impact of SecurityScorecard. The Interactive calculator will help organizations understand the Total Economic Impact of SecurityScorecard's holistic security rating platform.

The SecurityScorecard calculator is based upon the Forrester Consulting study, The Total Economic Impact of SecurityScorecard, commissioned by SecurityScorecard. Working with SecurityScorecard customers, Forrester identified and quantified key benefits of investing in SecurityScorecard's integrated approach to managing cybersecurity risk, including:

  • Increased efficiency in risk management
  • Technology efficiencies and consolidation
  • Improved security posture

“Organizations around the world are facing challenging financial climates, putting enormous pressure on CISOs to communicate value to their boards and leaders,” said Aleksandr Yampolskiy, CEO and co-Founder, SecurityScorecard. “Threat actors take advantage of turbulent times when staffing and resources tighten. The faster your team can prove value and justify your investments, the faster you can address your most critical issues.”

In addition to the ROI calculator, SecurityScorecard is also helping organizations improve the ROI of their security programs by giving them the ability to:

  • Achieve faster time to value by automating cybersecurity processes
  • Quantify risk in financial terms to the board and test different scenarios of potential impacts
  • Develop key metrics that the board cares about for defining, understanding, and quantifying cybersecurity threats
  • Set automated alerts and rules to prevent missed issues within the organization and any of its third-party vendors.

SecurityScorecard is also hosting a four-part, global webinar series to inform viewers about the key areas that leading security teams are prioritizing to proactively secure their organizations. The webinar series, which kicks off September 29th, will have dedicated sessions for North America, APAC and EMEA viewers and cover topics including:

  • Taking Control of Your Security in Turbulent Times
  • Carve Through the Noise by Prioritizing the Most Critical Threats
  • Show the Value of your Security Program
  • Showcase your Strong Security Posture to be the Vendor of Choice

Visit here to register for each webinar and learn more about how SecurityScorecard is helping organizations ensure double the return on investment on security awareness and prevention, hold vendors accountable, prioritize further areas of investment, and calculate your ROI estimate.

About SecurityScorecard

Funded by world-class investors including Evolution Equity Partners, Silver Lake Waterman, Sequoia Capital, GV, Riverwood Capital, and others, SecurityScorecard is the global leader in cybersecurity ratings with more than 12 million companies continuously rated. Founded in 2013 by security and risk experts Dr. Aleksandr Yampolskiy and Sam Kassoumeh, SecurityScorecard's patented rating technology is used by over 30,000 organizations for enterprise risk management, third-party risk management, board reporting, due diligence, cyber insurance underwriting, and regulatory oversight. SecurityScorecard is the first cybersecurity ratings company to offer digital forensics and incident response services, providing a 360-degree approach to security prevention and response for its worldwide customer and partner base. SecurityScorecard continues to make the world a safer place by transforming the way companies understand, improve and communicate cybersecurity risk to their boards, employees and vendors. Every organization has the universal right to their trusted and transparent Instant SecurityScorecard rating. For more information, visit securityscorecard.com or connect with us on LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005109/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release

Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA® Commercialization in Central and Eastern Europe7.1.2026 08:30:00 CET | Press release

Exclusive agreement covers 13 Central and Eastern European markets Collaboration will help expand access to VANFLYTA for patients with newly diagnosed FLT3-ITD positive AML Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnose

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye